Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Acetazolamide to Prevent Post Operative CSF Leak
NCT02902133 · University of Miami · PHASE2 · withdrawn · last registry update 2020-04-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No participants were identified per inclusion/exclusion criteria” | – | Registry record, University of Miami |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-03-30Results posted on the registry: University of Colorado, Denver, Nifedipine extended release + Methazolamide (NCT02463357)
- 2020-12-22Phase 3 first posted: Mayo Clinic, Placebo + Acetazolamide (NCT04679389)
- 2020-11-05Also stopped (withdrawn): Children's Mercy Hospital Kansas City, Potassium Citrate + Acetazolamide (NCT00120731)
- 2020-11-02Phase 3 first posted: The First Affiliated Hospital of Zhengzhou University, Acetazolamide Levamisole (NCT04611373)
- 2020-09-29Phase 3 first posted: Damascus University, Rivaroxaban + Warfarin (NCT04569279)
- 2020-06-11Results posted on the registry: Mayo Clinic, Diazepam + Acetazolamide (NCT02904265)
- 2020-06-11Also stopped (terminated): Mayo Clinic, Diazepam + Acetazolamide (NCT02904265)
- 2020-02-05Results posted on the registry: Medical College of Wisconsin, Ketamine + Placebo (NCT02432456)
- 2019-07-01Results posted on the registry: Novartis Pharmaceuticals, Serelaxin (NCT01979614)
- 2019-05-10Results posted on the registry: Vincent Kan, Acetazolamide + Placebo (NCT03490916)
- 2019-05-10Also stopped (terminated): Vincent Kan, Acetazolamide + Placebo (NCT03490916)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision